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A B S T R A C T   
Mycoplasma hyopneumoniae is the causative agent of porcine enzootic pneumonia, a chronic respiratory disease, 
causing significant economic losses. Results from the 2015− 2016 MycoPath pan-European antimicrobial sus-
ceptibility monitoring survey of M. hyopneumoniae are presented. In total, 147 M. hyopneumoniae porcine isolates 
from Belgium, France, Germany, Great Britain, Hungary, Italy, and Spain were tested. One isolate per farm was 
retained from pigs that had not been recently treated with antimicrobial agents. The minimal inhibitory con-
centration (MIC) of 13 antimicrobial agents was determined in a central laboratory using a broth microdilution 
method, with Friis Medium, incubated at 35 ± 1 ◦C for 5–12 days. M. hyopneumoniae NCTC 10110 was used as 
Quality Control. MIC50/MIC90 (mg/L) values were: enrofloxacin 0.06/1; marbofloxacin 0.06/2; spiramycin 0.06/ 
0.25; tulathromycin ≤0.001/0.004; gamithromycin 0.06/0.5; tylosin 0.016/0.06; tilmicosin 0.06/0.5; florfenicol 
0.5/1; doxycycline 0.25/1; oxytetracycline 0.25/2; lincomycin 0.06/0.25; tiamulin 0.016/0.06 and valnemulin 
≤0.001/0.004. Compared with the data from 2010 to 2012 MycoPath study (50 isolates), MIC50/90 results were 
similar and the majority were within ± two dilution steps, except for the MIC50 of oxytetracycline which is more 
than two dilution steps higher in the present study. Between-country comparisons show some differences in the 
MIC values for the fluoroquinolones, tulathromycin and tylosin, but the limited sample size per country pre-
cludes performing meaningful country comparisons for several countries. Standardized laboratory methods and 
interpretive criteria for MIC testing of veterinary mycoplasmas are clearly needed; there are currently no clinical 
breakpoints available to facilitate data interpretation and correlation of MICs with in vivo efficacy.   
1. Introduction 
Mycoplasma hyopneumoniae is the cause of enzootic pneumonia in 
pigs and one of the major pathogens involved in the porcine respiratory 
disease complex (PRDC). The pathogen causes major economic losses to 
the pig industry worldwide, mainly due to reduced performance, higher 
antimicrobial use and predisposing the animals to other respiratory in-
fections (Thacker and Minion, 2012; Pieters and Maes, 2019), with 
bacteria including Pasteurella multocida, Actinobacillus pleuropneumoniae 
and Streptococcus suis (Maes et al., 2008; Marois et al., 2009; 
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Marois-Créhan et al., 2020). M. hyopneumoniae potentiates the severity 
of Betaarterivirus suid 1 (International Committee on Taxonomy of Vi-
ruses (ICTV, 2019), formerly named porcine reproductive and respira-
tory syndrome virus (PRRSV) (Thacker et al., 1999; Marois-Créhan 
et al., 2020), and porcine circovirus type 2 (PCV2) associated pneu-
monia in pigs (Seo et al., 2014; Marois-Créhan et al., 2020). Commercial 
vaccines are available but do not prevent colonisation of the respiratory 
tract (Maes et al., 2008; Arsenakis et al., 2017). Consequently antimi-
crobial agents are often needed to treat and help control infections 
(Maes et al., 2018). Various antimicrobial agents are effective and 
licensed for treating M. hyopneumoniae infections. Potentially active 
antimicrobial agents against M. hyopneumoniae include amino-
glycosides/aminocyclitols, fluoroquinolones, lincosamides, macrolides, 
phenicols, pleuromutilins and tetracyclines (Gautier-Bouchardon, 2020; 
Maes et al., 2020). Mycoplasma species lack a cell wall and are therefore 
refractory to all antimicrobial agents that target the cell wall such as 
β-lactams (Wu et al., 1997; Lysnyansky and Ayling, 2016). Sulfonamide 
antimicrobial agents are also ineffective because mycoplasmas do not 
synthesize folic acid (Gautier-Bouchardon, 2018). 
Antimicrobial resistance of bacterial pathogens is of concern for the 
antimicrobial therapy of both humans and animals. Harmonized and 
continuous monitoring of antimicrobial susceptibility trends over time is 
an important component of stewardship to ensure long-term antimi-
crobial efficacy. However, recent antimicrobial susceptibility data of 
M. hyopneumoniae is rather limited, in contrast to Mycoplasma bovis 
susceptibility data (e.g., Heuvelink et al., 2016; Cai et al., 2019). 
Moreover, there are limitations in the available M. hyopneumoniae data, 
as published studies either have a limited number of isolates, or are only 
from one country (Hannan et al., 1997a; Vicca et al., 2004; Tavío et al., 
2014). In other studies the epidemiological sampling framework, or 
herd information is either limited or absent (Hannan et al., 1997a, 
1997b). Historic M. hyopneumoniae antimicrobial susceptibility data 
may be of limited value today due to decades of altered antimicrobial 
consumption. In none of the European national, ongoing programmes 
such as GERM-Vet (Germany), RESAPATH (France) or UK-VARSS (Great 
Britain) are these organisms included. Hence, there is need for recent 
M. hyopneumoniae antimicrobial susceptibility data to resolve the above 
limitations. 
The present study was conducted as part of the Centre Européen 
d`Etudes pour la Santé Animale (CEESA) monitoring programmes (de 
Jong et al., 2013). The MycoPath programme aims to create a 
pan-European collection of representative Mycoplasma pathogens iso-
lated from clinical cases of diseased poultry (Mycoplasma gallisepticum 
and Mycoplasma synoviae), cattle (M. bovis), and pigs 
(M. hyopneumoniae) that have not recently been exposed to antimicro-
bial agents. These isolates are used to monitor the in vitro susceptibility 
of licensed antimicrobial agents and can also be used by pharmaceutical 
companies to assess the in vitro effectiveness of any new antimicrobial 
agents being developed. Antimicrobial susceptibilities of 
M. hyopneumoniae recovered from seven European countries are pre-
sented here. This is the second study (MycoPath II) to include 
M. hyopneumoniae as part of the CEESA monitoring programmes, so 
comparisons can be made with the previous study (MycoPath I; Klein 
et al., 2017). 
2. Methodology 
2.1. Mycoplasma hyopneumoniae collection 
During 2015 to 2016 M. hyopneumoniae isolates were obtained 
following post-mortem sampling of pigs. Pigs were aged from three 
weeks to seven months with clinical signs of respiratory disease or from 
slaughterhouse lung samples with pathology consistent with enzootic 
pneumonia. Samples had to meet specific criteria which included lack of 
antimicrobial treatment in the previous 15 days, with only one isolate 
per farm. The participating laboratories were from Belgium, France, 
Germany, Great Britain, Hungary, Italy and Spain. In an attempt to 
achieve identical numbers of isolates from the participating countries, a 
target number of 40 isolates were indicated for each country. The ma-
jority of the participating countries followed their standard Mycoplasma 
culture isolation and molecular identification procedures (Mattisson 
et al., 1995; Moronato et al., 2017); the samples from Germany and 
Spain as well as some of the British samples were sent for isolation and 
identification to the central laboratory (Don Whitley Scientific, Bingley, 
UK). Isolates were stored at -70 ± 10 ◦C, before transfer to the central 
laboratory for antimicrobial susceptibility testing. 
At the central laboratory the isolates were checked for viability with 
M. hyopneumoniae being cultured in Friis medium (Friis, 1975). Each 
culture was grown and the viable count determined by plating onto the 
agar medium so that the cell density could be adjusted to 106 CFU/mL 
for the minimal inhibitory concentration (MIC) tests. In addition to the 
identification of the British, German and Spanish isolates at the central 
laboratory, identity was confirmed for eight randomly selected 
M. hyopneumoniae isolates (5.4 %) using a duplex PCR method that 
identified both M. hyopneumoniae and M. hyorhinis giving a 430 bp and 
346 bp amplicon, respectively (Barate et al., 2012). The identity of the 
eight isolates was confirmed. 
2.2. Antimicrobial testing 
Antimicrobial susceptibility testing used a broth microdilution 
method to determine the MICs to 13 antimicrobial agents. The antimi-
crobial agents included in this study belong to six frequently used 
chemical classes: the phenicols (florfenicol); the fluoroquinolones 
(enrofloxacin, marbofloxacin); the macrolides and modified macrolides 
(gamithromycin, spiramycin, tilmicosin, tulathromycin, tylosin); the 
pleuromutilins (tiamulin and valnemulin); the tetracyclines (doxycy-
cline and oxytetracycline) and the lincosamides (lincomycin). The 
antimicrobial agents were obtained as: doxycycline hyclate; enro-
floxacin; florfenicol; lincomycin hydrochloride; marbofloxacin; oxytet-
racycline hydrochloride; spiramycin; tiamulin fumarate; tilmicosin; 
tylosin tartrate (all from Sigma-Aldrich, UK); gamithromycin (Merial; 
France); tulathromycin (Pfizer, USA); and valnemulin hydrogen tartrate 
(European Directorate for the Quality of Medicines and Healthcare, 
France). The preparation of the stock solutions of the antimicrobial 
agents has been described recently (Klein et al., 2017, 2019), except for 
doxycycline, lincomycin and tilmicosin. Doxycycline and lincomycin 
were prepared in deionized water, whereas tilmicosin was dissolved in 
95 % ethanol before being made to the correct final volume with 
deionized water. It should be noted that the importance of correct 
buffering of tulathromycin in the MIC test to avoid artificial MIC shifts 
(Godinho, 2008) was respected in our study. 
The determination of MIC values for each isolate has been performed 
as previously described (Klein et al., 2017). In short, the MICs of the 13 
antimicrobial agents were determined using a broth microdilution 
method, with Friis Medium (without bacitracin and methicillin), incu-
bated at 35 ± 1 ◦C. The incubation period required to produce clearly 
readable MIC endpoints varied between 5 and 12 days, according to the 
individual M. hyopneumoniae strains. The type strain M. hyopneumoniae 
NCTC 10110 (ATCC 25934) was used as a Quality Control (QC) for all 
MIC testing. In a number of cases MICs of the test isolates could not be 
assessed due to poor growth or loss of viability. In these cases the 
incomplete datasets were indicated in Tables 1 and 2. In cases where the 
MIC results obtained for an antimicrobial agent against one or more 
strains of M. hyopneumoniae deviated markedly from the MICs obtained 
against the majority of strains, the MIC test was repeated twice. In such 
cases, the reported MIC value was obtained on at least two separate 
occasions. 




Minimal inhibitory concentration (MIC in mg/L) values (range, MIC50, MIC90) of 13 antimicrobial agents against 147 Mycoplasma hyopneumoniae isolates from pigs obtained from seven different European countries 





ENR MAR DOX OTC FFC LC TIA VAL GAM TUL SPM TIL TYL 
Belgium (40 
isolates) 
Range 0.008–2 0.008–2 0.008–1 0.008–2 0.002–1 0.002->64 0.004–0.25 ≤0.001–0.008 ≤0.001–1 ≤0.001-≥128 0.002− 8 0.002− 64 0.002–16 
MIC50 0.063 0.031 0.25 0.5 0.25 0.063 0.016 ≤0.001 0.063 ≤0.001 0.063 0.031 0.004 
MIC90 0.25 0.5 0.5 1 0.5 0.5 0.063 0.002 0.5 8 0.5 0.5 0.5 
isolates 
tested 38 40 40 40 38 39 39 39 37 39 37 40 40 
France (10 
isolates) 
Range 0.008–0.25 0.016–0.063 0.031 -0.5 0.002–0.031 0.125–0.5 0.004–0.125 0.008–0.031 All ≤0.001 0.016–0.5 ≤0.001–0.002 0.063–0.25 0.125− 0.5 0.031–0.063 
MIC50 0.031 0.031 0.125 0.002 0.25 0.063 0.016 ≤0.001 0.5 0.002 0.125 0.25 0.063 
MIC90 0.063 0.063 0.25 0.016 0.5 0.125 0.016 ≤0.001 0.5 0.002 0.25 0.5 0.063 
isolates 
tested 
10 10 10 10 10 10 10 10 10 10 10 10 10 
Germany (15 
isolates) 
Range 0.016–2 0.031–2 0.031–1 0.016–1 0.031–1 0.002–32 0.004–0.125 ≤0.001–0.004 0.002–2 ≤0.001–8 0.004–16 0.004-≥128 0.002–16 
MIC50 0.25 0.5 0.063 0.125 0.5 0.125 0.031 ≤0.001 0.031 ≤0.001 0.063 0.125 0.016 
MIC90 2 2 0.25 0.25 1 0.5 0.125 0.002 0.5 0.008 16 0.5 0.063 
isolates 
tested 15 15 15 15 15 15 15 15 15 15 15 15 15 
Great Britain 
(25 isolates) 
Range 0.004–1 0.004− 1 0.004–1 0.031–4 0.002–1 0.002-≥128 ≤0.001–0.063 ≤0.001–0.004 ≤0.001- 
≥128 
≤0.001–16 0.008− 4 0.004− 64 ≤0.001–32 
MIC50 0.016 0.031 0.5 0.5 0.5 0.063 0.031 ≤0.001 0.125 0.002 0.125 0.125 0.031 
MIC90 0.125 0.5 1 1 1 0.5 0.063 0.002 1 0.008 4 1 0.125 
isolates 
tested 25 25 25 25 25 25 25 25 25 25 25 25 25 
Hungary (43 
isolates) 
Range 0.008–4 0.004–4 0.031–1 0.063–4 0.063–1 0.002-≥128 0.002–0.125 ≤0.001–0.004 0.004− 0.5 ≤0.001–0.002 0.008–16 0.004− 64 0.004–32 
MIC50 0.125 0.5 0.25 0.5 0.5 0.125 0.016 0.002 0.031 <0.001 0.063 0.063 0.031 
MIC90 2 2 1 2 1 0.25 0.063 0.004 0.125 0.002 0.25 0.25 0.063 
isolates 
tested 
43 43 43 43 43 43 43 43 43 43 43 43 43 
Italy (5 isolates) 
Range 1–2 2− 2 0.25–1 0.031–0.25 0.5–0.5 0.002–0.008 0.016–0.063 All ≤0.001 0.004–0.063 All ≤0.001 0.004–0.031 0.002− 0.063 0.002− 0.016 
MIC50 1 2 0.5 0.031 0.5 0.004 0.016 ≤0.001 0.004 ≤0.001 0.008 0.004 0.002 
MIC90 ND ND ND ND ND ND ND ND ND ND ND ND ND 
isolates 
tested 2 2 5 5 5 5 5 5 2 4 5 4 5 
Spain (9 
isolates) 
Range 0.031–2 0.12–4 0.12–1 0.063–1 0.004–0.5 0.002–0.12 0.002–0.12 ≤0.001− 0.002 0.004–2 ≤0.001–0.008 0.008–0.5 0.031− 0.5 0.016–16 
MIC50 1 2 0.5 0.25 0.25 0.031 0.031 ≤0.001 0.25 0.002 0.125 0.25 0.031 
MIC90 ND ND ND ND ND ND ND ND ND ND ND ND ND 
isolates 
tested 9 9 9 9 9 9 9 9 9 9 9 9 9 
All (147 
isolates) 
Range 0.004–4 0.004–4 0.004–1 0.002–4 0.002–1 0.002-≥128 ≤0.001–0.25 ≤0.001–0.008 
<0.001- 
≥128 ≤0.001-≥128 0.002–16 0.002-≥128 ≤0.001–32 
MIC50 0.063 0.063 0.25 0.25 0.5 0.063 0.016 ≤0.001 0.063 ≤0.001 0.063 0.063 0.016 
MIC90 1 2 1 2 1 0.25 0.063 0.004 0.5 0.004 0.25 0.5 0.063 
isolates 
tested 
142 144 147 147 145 146 146 146 141 145 144 146 147 
QC MIC range 
0.031− 0.063 
(12) 0.063 (7) 
0.125− 0.5 



















ENR = enrofloxacin; MAR = marbofloxacin; DOX = doxycycline; OTC = oxytetracycline; FFC = florfenicol; LC = lincomycin; TI A = tiamulin; VAL = valnemulin; GAM = gamithromycin; TUL = tulathromycin; 
SPM = spiramycin; TIL = tilmicosin; TYL = tylosin. 
ND = MIC90 not determined. QC: Mycoplasma hyopneumoniae (NCTC 10,110) was used as a quality control standard in this study; number of MIC determinations is indicated in parentheses. 
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3. Results 
3.1. Mycoplasma hyopneumoniae collection 
Despite intensive efforts by participants in each country, it was not 
possible for all of them to obtain the target number (n = 40) of isolates, 
mainly because animals were treated prior to sampling. Records of all 
samples indicated that 85.9 % of the sampled pigs had not been exposed 
to antibacterial treatment for at least 15 days prior to sampling. The 
remaining 14.1 % of the samples were from animals with a treatment 
status characterized as “unknown”. Ultimately we succeeded to obtain a 
total of 147 M. hyopneumoniae isolates associated with respiratory dis-
ease, 40 from Belgium, 10 from France, 15 from Germany, 25 from Great 
Britain, 43 from Hungary, 5 from Italy and 9 from Spain. Sixty-one 
isolates (41.5 %) were recovered from samples taken in 2015; 86 iso-
lates (58.5 %) were from samples of 2016. The very limited number of 
isolates for Italy and Spain prevents comparison with other countries. 
Therefore comparisons in this results section are limited to countries 
with ten or more isolates. The majority of the lung samples (72.8 %) 
were taken at abattoirs, from tissue lesions of fatteners at an age of 
25–28 weeks old. The herd size varied widely, e.g., in Belgium from 80 to 
2400 pigs, in Germany from 520 to 18,000 pigs and in Hungary from 
120 to 13,500 pigs. Each isolate included in the study was from a 
different farm. 
3.2. Antimicrobial susceptibilities (Tables 1 and 2) 
For each antimicrobial agent, M. hyopneumoniae MIC results for in-
dividual countries and for all isolates are presented as MIC range, MIC50 
and MIC90 in Table 1. The number of isolates tested, which varies per 
country per antimicrobial due to a few non-viable isolates, is also listed. 
Table 1 also includes the MIC values of the reference type strain. Fre-
quency distributions of MIC results are presented in Table 2. 
For both of the fluoroquinolones enrofloxacin (142 isolates) and 
marbofloxacin (144 isolates) a bimodal or multimodal MIC distribution 
was observed and the MIC50 for these isolates was 0.063 mg/L, with an 
MIC90 value of 1 and 2 mg/L respectively. Belgium, France and Great 
Britain had MIC50 and MIC90 fluoroquinolone values that were 2–3 di-
lutions lower than those for Germany and Hungary. 
Doxycycline and oxytetracycline antimicrobial agents gave similar 
MIC50 and MIC90 values of 0.25/1 and 0.25/2 mg/L, respectively. 
However doxycycline MIC50 and MIC90 values for Germany were 0.063 
and 0.25 mg/L whereas oxytetracyline MICs were lower for France at 
0.002 and 0.016 mg/L respectively. Florfenicol had similar MIC range 
0.002–1 mg/L and MIC50 values of 0.25 to 0.5 mg/L, and MIC90 values 
of 0.5–1 mg/L for all countries. For all three compounds, a broad 
monomodal MIC distribution pattern was seen. 
Belgium, Germany, Great Britain and Hungary had some isolates 
with high lincomycin MIC values at 32 and ≥128 mg/L, although the 
MIC50 and MIC90 values all had a range of 0.063 to 0.125 mg/L and 
0.125 to 0.5 mg/L, respectively. Low MIC ranges and MIC50/90 values 
were observed for both pleuromutilin antimicrobial agents from all 
countries: MIC range of ≤0.001 to 0.25 mg/L and MIC50/90 0.016/ 
0.063 mg/L for tiamulin and MIC range ≤0.001 to 0.008 mg/L and 
MIC50/90 ≤0.001/0.004 mg/L for valnemulin. Overall, a multimodal 
MIC pattern was observed. 
The macrolides and modified macrolides displayed MIC50/90 values 
of 0.063/0.5 mg/L for gamithromycin; 0.063/0.25 mg/L for spi-
ramycin; 0.063/0.5 mg/L for tilmicosin; ≤0.001/0.004 mg/L for tula-
thromycin and 0.016/0.063 mg/L for tylosin. For gamithromycin 
France had the highest MIC50 value at 0.5 mg/L but the MIC90 value at 
0.5 mg/L was comparable to the other countries with Great Britain 
having the highest MIC90 value of 1 mg/L. Great Britain also had the 
highest MIC90 value of 1 mg/L for tilmicosin compared to 0.25 – 0.5 mg/ 
L for the other countries. For tulathromycin, Belgium had a MIC90 value 
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Multimodal MIC patterns were observed. 
4. Discussion 
In this study, 13 antimicrobial agents were tested against 147 
M. hyopneumoniae isolates from seven European countries, and was 
therefore more extensive than the previous study (Klein et al., 2017) in 
which 9 antimicrobial agents were tested against 50 isolates from three 
countries. To ensure consistency, a central laboratory performed all the 
MIC testing and used the same method as described previously (Klein 
et al., 2017), following the guidelines of Hannan (2000). This approach 
facilitates broad comparisons between the two studies. Although a few 
isolates gave high MIC values, overall the MIC50 and MIC90 values for all 
of the antimicrobial agents are low, less than 0.5 and 2 mg/L respec-
tively when compared to MICs obtained for M. bovis (Ayling et al., 2014; 
Klein et al., 2017; 2019). The authors are unaware of any collection of 
M. hyopneumoniae isolates that is as representative of the European 
population of pigs, both in size and geographic diversity. 
MIC interpretation criteria are not available for M. hyopneumoniae. 
Generally antimicrobial susceptibility testing for veterinary Mycoplasma 
species lacks quality control strains with specified MIC ranges, test 
methods and breakpoints (Maes et al., 2018), although guidelines have 
been published (Hannan, 2000). Standards for the Mycoplasma testing of 
significant clinical infections in humans (Mycoplasma pneumoniae, My-
coplasma hominis, and Ureaplasma urealyticum) have been published 
(CLSI, 2011; Waites et al., 2012). However, the growth requirements of 
these Mycoplasma species that occur in humans differ significantly from 
M. hyopneumoniae. Therefore the growth media that are suitable for 
testing these human derived Mycoplasma species cannot be applied to 
livestock species. It is important to note that, in addition to the CLSI 
standards for human mycoplasmas, a EUCAST Veterinary Subcommittee 
on Antimicrobial Susceptibility Testing (VetCAST) has recently been 
established. One of the remits of VetCAST is to initiate and coordinate 
EU research aimed at filling the current gaps on veterinary-specific 
breakpoints including epidemiological cut-offs (ECOFFs) values (Tou-
tain et al., 2017). 
It should be underlined that the numbers of isolates tested are too 
small to draw definitive conclusions about potential country differences. 
In addition, all QC MIC values were within two dilutions, except for 
gamithromycin, spiramycin and tiamulin (three dilutions). The MIC 
ranges for these three compounds obtained for the type culture strain 
precludes valid data about subtle MIC shifts. The central laboratory 
standardised the testing so these differences are hard to explain. It might 
be due to the low number of QC tests (7–14). Hannan (2000) reported 
variations in MIC values from 0.01 to 0.1 mg/L for tiamulin and 
0.25–2.5 mg/L for spiramycin due to differences in inoculum size, other 
factors such as growth phase and incubation times could also affect the 
MIC value. However, the reproducibility of the MICs harvested from the 
field isolates was high. Further work is required to standardize the MIC 
test methodology for veterinary Mycoplasma species. 
With respect to several potential MIC differences between countries 
(Table 1), it is tempting to investigate the relationship between anti-
microbial consumption for the treatment of bacterial infections and the 
MIC levels. Regrettably, historic data on the antimicrobial consumption 
on the specific farms where the samples were obtained is not available. 
Several years ago the European Surveillance of Veterinary Antimicrobial 
Consumption (ESVAC) was established to collect data on the use of 
antimicrobial agents in animals in Europe (EMA, 2019). The uniform 
record of the national antibiotic consumption in veterinary medicine is 
highly valuable. However, only the total consumption per country per 
annum is being reported. The lack of consumption data per animal 
species or clinical indication such as mycoplasmoses in pigs, limits at-
tempts to explain any differences in antimicrobial susceptibilities be-
tween countries and over time. In the meantime quantification of 
antibiotic use has become mandatory in several countries, e.g. Belgium, 
The Netherlands and Denmark. This will facilitate future investigations 
into the association between antibiotic use and antimicrobial suscepti-
bility results obtained for M. hyopneumoniae isolates. 
Comparison of the MIC50 and MIC90 values between this study 
(MycoPath II) and that of Klein et al. (2017) (MycoPath I) showed minor 
differences. When individual country data is examined (Table 1), there 
is an apparent increase in the maximum MIC of valnemulin from 0.002 
to 0.004 mg/L for Great Britain and to 0.008 mg/L for Belgium. For 
tulathromycin the overall MIC50 and MIC90 remain low at ≤0.001 and 
0.004 mg/L respectively, but some isolates from Belgium and Great 
Britain had tulathromycin MIC values of 16 mg/L and as high as 
≥128 mg/L. Although there are limitations and a risk of over inter-
pretating data from this study, an increase in oxytetracycline MIC50 
values for the three countries included in the previous studies from 
0.063 to 0.5 mg/L for Belgium, 0.063 to 0.25 mg/L for Spain and 0.031 
to 0.5 mg/L for Great Britain indicates a genuine rise in MIC levels. 
Some MIC increases can be explained by the inclusion of additional 
countries in this study; for example Germany, Hungary and Italy had 
higher MIC50 and MIC90 values than Belgium, France and Great Britain 
to the fluoroquinolones enrofloxacin and marbofloxacin. In order to 
avoid any bias, we have therefore compared the MIC values of isolates 
from the three countries (Belgium, Great Britain and Spain) which were 
common in both the MycoPath I and MycoPath II surveys (Table 3). 
Compared to the 2010–2012 study, an MIC50 increase of three doubling 
dilutions is observed for oxytetracycline. MIC90 values increases of two 
doubling dilutions were noted only for oxytetracycline, valnemulin and 
tylosin as compared to the 2010–2012 study. However, these minor 
shifts should not be over interpreted; most changes are within the 
normal fluctuation indicated by CLSI of ± one dilution step. 
The results of the NCTC strain 10110 used for QC showed some 
differences between MycoPath I (Klein et al., 2017) and this study (data 
included in Table 1), particularly for oxytetracycline, tiamulin, tula-
thromycin and tylosin, where there appeared to be a general increase. 
For example, for oxytetracycline the MIC range was 0.125− 0.25 mg/L 
in MycoPath I and 0.25− 1 mg/L in MycoPath II. These small differences 
are hard to explain. It might be due to the limited number of QC tests in 
MycoPath I (< 5). One could also postulate that minor variations be-
tween reference strain batches between MycoPath I and MycoPath II 
could have resulted in variation in metabolism and growth rates 
affecting some antimicrobial agents differently, although QC was car-
ried out on the commercially obtained media which supported 
M. hyopneumoniae growth. However, the reproducibility of the field 
isolates MIC values was high. 
Another study (Felde et al., 2018) mainly tested isolates from 
Hungary (n = 40), Slovakia (n = 3) and Czech Republic (n = 1), using a 
similar broth microdilution method, but with Mycoplasma Experience 
broth medium (Mycoplasma Experience Ltd., Bletchingley, UK). With 
Table 3 
Comparison of Minimal Inhibitory Concentration (MIC in mg/L) data for My-
coplasma hyopneumoniae of three countries (Belgium, Great Britain and Spain) 
between this study (MycoPath II) and the previous study (MycoPath I; Klein 
et al., 2017).  
Antimicrobial agent 
MycoPath I  MycoPath II 
MIC50 MIC90 n MIC50 MIC90 na 
Enrofloxacin 0.031 0.5 50 0.063 1 72 
Marbofloxacin 0.031 0.5 50 0.031 1 74 
Oxytetracycline 0.063 0.25 50 0.5 1 74 
Florfenicol 0.25 0.5 50 0.25 0.5 72 
Tiamulin 0.016 0.063 50 0.016 0.063 73 
Valnemulin ≤0.001 ≤0.001 50 ≤0.001 0.002 73 
Tulathromycin ≤0.001 0.004b 50 ≤0.001 0.008 73 
Spiramycin 0.063 0.25 50 0.063 0.5 71 
Tylosin 0.031 0.125 50 0.016 0.5 74  
a Number of Belgian isolates tested varied between 37 and 40, as indicated in 
Table 1. 
b MIC90 value recalculated from Klein et al. (2017). 
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the exception of valnemulin and enrofloxacin all of the antimicrobial 
agents tested by Felde et al. (2018) had higher MIC50 and MIC90 values. 
In comparison with the present study, the main difference between the 
tests was the growth medium. This may have influenced the test results, 
arguably the growth medium used may have given better control 
growth, however the medium formula is not published and it is possible 
that the medium contained anti-fungal and antimicrobial agents that 
may interfere with the MIC test. With longer incubation times the 
antimicrobial agents under test may start breaking down, or induce or 
select for antimicrobial resistance (Gautier-Bouchardon, 2018). How-
ever, the incubation time in the study of Felde et al. ranged from 4 to 14 
days (Felde et al., 2018), whereas in our work it was 5–12 days. It is 
therefore unlikely that measuring any mycoplasmacidal effect rather 
than the inhibitory effect explains the differences. The MICs are per-
formed on cells that should be in a planktonic state, as they are tested in 
a broth medium. However it is known that some M. hyopneumoniae 
strains have the ability to form biofilms, in which state they can 
potentially survive in ten-fold higher concentrations of antibiotics 
(Tassew et al., 2017). Although it is questionable whether 
M. hyopneumoniae will have enough time to form biofilms in MIC plates, 
this may be another possible explanation for some differences in results 
between published studies. 
The occurrence of isolates with high MICs for lincomycin, gami-
thromycin, tulathromycin, tilmicosin and tylosin (MICs ≥ 32 mg/L) 
might indicate that these isolates might have a resistance determinant. 
However, since breakpoints have not yet been determined for 
M. hyopneumoniae, the efficacy of an antimicrobial therapy cannot be 
predicted. It should be noticed that the MIC distribution only reflects the 
potency of an agent against a specific pathogen in vitro. The potential for 
developing antimicrobial resistance is evident from other Mycoplasma 
species, but also for M. hyopneumoniae which has been demonstrated in 
Tibet with macrolide resistance shown by mutations in the 23 rRNA 
gene (Qiu et al., 2018). Other reports have previously indicated anti-
microbial resistance to some macrolides and lincosamides (Stakenborg 
et al., 2005; Thongkamkoon et al., 2013; Felde et al., 2018; Gau-
tier-Bouchardon, 2018) and fluoroquinolones (Vicca et al., 2007; Felde 
et al., 2018). Mutations in the parC and gyrA genes have shown corre-
lation with decreased fluoroquinolone susceptibility of 
M. hyopneumoniae. In other studies (on M. bovis isolates) alterations 
related to elevated tetracycline MICs were described in several positions 
of genes encoding 16S rRNA and mutation in the rrs1 gene was related to 
a high spectinomycin MIC (Sulyok et al., 2017). Genetic mutations are 
known to relate to antimicrobial resistance and they demonstrated that 
the number of mutations also related directly to MIC values (Lerner 
et al., 2014). Mechanisms of antimicrobial resistance are outside the 
scope of this study. Studies need to be done to establish the relationship 
between genetic mutations and MIC values for M. hyopneumoniae and 
the potential role of plasmids, efflux or novel mechanisms for develop-
ment of antimicrobial resistance by Mycoplasma species. Reviews of 
mechanisms of resistance and trends in antimicrobial susceptibility of 
Mycoplasma species were published by Lysnyansky and Ayling (2016) 
and Gautier-Bouchardon (2018). 
It is important to monitor if isolates with high MIC values occur 
among M. hyopneumoniae and to determine the underlying resistance 
mechanism, so that only effective antimicrobial agents are used for 
therapy thus ensuring minimal use of antimicrobial agents by using 
targeted and correct treatments. In vitro MIC results do not necessarily 
correlate to the effectiveness of the antimicrobial agents in vivo and 
hence interpretation of the MIC distributions is made difficult as veter-
inary Mycoplasma species do not have defined clinical breakpoints. As 
seen when comparing the results from this study and that of Felde et al. 
(2018), even minor differences in methods may affect results, so this 
reinforces the urgent need for veterinary Mycoplasma-specific laboratory 
standards and clinical breakpoints for MIC data interpretation of My-
coplasma species. Comparison of the data from this study and the pre-
vious study indicates that most MIC values were similar; there was only 
a minor increase in MIC values for oxytetracycline (Klein et al., 2017). It 
however remains essential that the MycoPath monitoring programmes 
continue to monitor antimicrobial in vitro effectiveness. 
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